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Multiple sclerosis is an inﬂammatory disease leading to disseminated lesions of the central nervous system resulting in both
somatomotor and autonomic disturbances. These involve the central centers of the autonomic nervous system, as well as the
automatic control and pathway systems. All autonomic functions may be disordered individually or in combined form. There
is no other disease with a clinical picture so multifaceted. Besides cardiovascular dysfunctions disorders of bladder and rectum
have become apparent. Somatomotorand autonomicdisturbances occur with similar frequency; however the focused exam often
heavily favors somatomotor symptoms. Autonomic disturbances should primarily be taken into account on history taking and
clinical examination. Individual diagnosis and treatment is a secondary feature. Impairments of the autonomic nervous systems
in multiple sclerosis are frequently overlooked.
1.Introduction
Although there are obvious disturbances of the somatic and
autonomic nervous system in disseminated CNS-disease,
in the diagnosis and therapy of multiple sclerosis there is
less focus on the autonomic nervous system than on the
somatic nervous system. Vegetative symptoms are mostly
recorded without classifying them to a morphologic lesion
as is being done with motor and sensory deﬁcits. By com-
parison withsomaticsymptoms, autonomicdisturbancesare
widely disregarded in the literature as well as in scientiﬁc
research. A great number of autonomic dysfunctions are
not being attended to by neurologists but by other medical
specialists. This leads to deﬁcits in the diagnostic workup
and treatment of the illness, as patient management is
neither centralized nor coordinated. It should principally be
the neurologist’s responsibility to guide diagnostics and to
includehis reﬂections and observations in the treatment that
has been recommended and carried out.
Any vegetative function can be impaired due to the
dissemination of the lesions. Reference in this respect is, of
course, made to the autonomic nervous system (Figure 1).
Since the lesion is rarely aﬀecting one area alone, we
frequently see a complex constellation of symptoms that
can be both, progressing as well as regressing. This holds
particularly true for myelin, the pathways of which may
be aﬄicted, and on the other side for the sympathetic and
parasympathetic systems that may be disrupted in varying
degrees.
Symptoms involve the entire autonomic nervous system,
especially the urogenital tract, gastrointestinal tract, and the
cardiovascular system.
2.Dysfunctions ofthe Bladder
Regulation of urinary storage and urinary evacuation is
highly complex involving many structures of the central
nervous system. This is why urologic symptoms are frequent
and typical sequelae of inﬂammation-induced lesions of
the central nervous system. In 5–9% of patients, urologic
symptoms represent the ﬁrst manifestation of multiple
sclerosis [1, 2]. In later stages of this illness, approximately
80–90+% of all patients are dealing with bladder dysfunction
[3–6]. In theory, bladder dysfunction may be episodic with
intermittent acute symptoms, which may complicate the
diagnostic process.
The topographically disseminated pathologic activity of
multiple sclerosis (MS) does damage to various centers (pre-
dominantly the frontal and pontine micturition center and2 Autoimmune Diseases
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Figure 1: Focal points of the autonomicnervous system.
the spinal cord) aside from other structures of the complex
control loopofneurogenic bladderregulation. Lesions above
thepontinemicturitioncenterwillleadtoreducedinhibition
and, consequently, to hyperactivity of the detrusor muscle;
meaning the urge to urinate in the absence of adequate
bladder ﬁlling. Spinal lesions in the cervical and thoracic
marrow will also result in diminished central inhibition
via damage to the sensory aﬀerences and to the pyramidal
tract. Lesions in this area result not only in hyperactivity
of the detrusor but also in disrupted coordination between
detrusor contractions and sphincter relaxation (detrusor
s p h i n c t e rd y s s y n e r g y ) .I na d d i t i o n ,d a m a g et ot h ep y r a m i d a l
tracts will generate spasticity of the striated sphincters.
Detrusor hypoactivity is considerably rarer and frequently
secondary in nature [7]. Overall, the correlation between the
character of bladder dysfunction and the pattern of lesions
seen on magnetic resonance imaging (MRI) appears to be
rather poor; on the other hand the correlation between the
degree of bladder dysfunction and the degree of disability
and pyramidal malfunction was corroborated by quite a few
authors [7–9].
3.NeurologicDiagnosis
The diagnosis of bladder dysfunctions in patients with mul-
tiple sclerosis is frequently drawn from accessory remarks
(ancillary information) on history taking. The examiner
should always and explicitly inquire about diﬃculties asso-
ciated with urination. Polyuria is often the ﬁrst symptom
patients mention. In addition, they complain of new-
onset nocturia. Increased nighttime micturitions are often
dismissed. Contrarily urgesymptoms, which are experienced
in the further course of disease, are usually reported sponta-
neously against the background of imminent or rare urinary
incontinence. Urinary tract infections do not play a major
symptom-deﬁning role at this stage of bladder dysfunction.
Diﬃculty voiding is a rare urologic ﬁrst symptom of
multiple sclerosis. It is generally reported at once and should
be diagnosed and treated without delay to prevent acute
complications as well as detrusor and kidney alterations
before their manifestation as secondary long-term sequelae.
In later stages of the disease, there is clinical evidence of
both diﬃculty voiding as well as insuﬃcient storage. While
increases in urinary frequency and incontinence primarily
lead to social restrictions, increased residual urine causes
concomitant urinary tract infections. Contrary to traumatic
paraplegia, lesions ofthe upperurinary tract are signiﬁcantly
less common in female patients with MS [10], but they
never cease to be a possible complication in the disease
progression [11]. Aggravated bladder dysfunction is mostly
associated with gradually progressing dysfunction of sensory
and particularly motor pathways to the lower limbs.
Studying bladder ﬁlling and evacuation by video uro-
dynamics permits the clearest analysis of impaired bladder
function. The parameters monitored include internal vesic-
ular pressure, intrarectal pressure, voided volume, urinary
ﬂow and muscular activity of the pelvic ﬂoor. At the onset of
voiding (i.e., detrusor contraction) MS patients will typically
present with a higher muscle tone in the pelvic ﬂoor,
which is passed on to the vesical sphincter muscle, thereby
impeding the process of urination. This ﬁnding has been
termed detrusor sphincter dyssynergy (DSD). Sonographic
determination of residual urine is insuﬃcient to conclusively
determine the exact nature of the dysreﬂexia; however
residual volume is the most relevant clinical factor in this
classiﬁcation. It is therefore appropriate for an overall check
on the eﬀect and on the necessity of treatment.
The validity of neurophysiologic tests is limited. Sensory
evokedpotentials(SEPs) ofthe pudendalnerveare helpfulin
objectifying theextentofaﬀerentdamage.Electromyography
(EMG) of the striated sphincters may provide clues to
diﬀerential diagnosis.
Theremaybeadditionalbladderdysfunctionsapart from
MS typical DSD, and these have to be excluded in terms of
diﬀerential diagnosis. This applies to prostatic hyperplasia
in older male subjects or symptoms of stress incontinence
present in older women.
4.TreatmentofBladderDysfunctions
Drug therapy of DSD is aimed at two aspects: suppression of
t h eu r g et op a s sw a t e ro rt h eo v e r l yf r e q u e n tr e ﬂ e x i v ev o i d i n g
ofthebladder,andsecondarilytherelaxationofthesphincter
tonus to improve urinary output.
The inhibition of detrusor hyperactivity is accom-
plished by drug-induced suppression of the parasympathetic
innervation—primarily by the application of anticholinergic
agents. In case of unsatisfactory eﬀect, local injection of
botulinum toxin might be appropriate for some patients
[12, 13]. Patients with mild urge incontinence can beneﬁt
from the anticholinergic action of tricyclic antidepressants.
Initiation of treatment as described bears the risk of accu-
mulating residual urine; therefore, it is necessary to monitor
residual volume during the initial phases of treatment. This
also appliestootherparasympatholytic orsympathomimetic
medication. Concomitant treatment ofthedrainage disorder
is required at the latest when residual urine has come up to
more than 100mL. Antispasmodics, used previously in the
course of treatment for symptoms not relating to problems
withthebladderbecometheagentofchoice.Bladdertrouble,
in some cases, may be the only indication for their long-term
application. Despite diﬀerentiated medication, we cannotAutoimmune Diseases 3
always prevent stagnant urine from worsening or preserve
the ability to retain urine. These two problems can usually
be resolved by intermittent self-catheterization. There are
physical prerequisites to that, namely, adequate manual skills
and a fairly low adductor tonus. An indwelling catheter is
the provisionary solution for patients who do not meet these
requirements or who are likely to fail in self-catheterization
for whatever reason.
Sacral neuromodulation [14] has been successful in only
a few MS patients and is therefore not recommended.
Physiotherapeutic approaches and rehabilitation pro-
grams [15] are suitable to enhance pharmacotherapy.
Training of the muscular system of the pelvic ﬂoor and
biofeedback methods can be contributory to maintaining
continence and in supporting relaxation of the external
sphincter muscle (to avoid triggers for instance).
4.1. Sexual Dysfunctions. The most thoroughly researched
solitary sexual problem is erectile dysfunction in males
suﬀeringfromMS.Inneurologicalliterature,includingolder
publications, the incidence is rated approximately: 60% [16–
19]. A sexual science study on MS patients in Northern
Germany revealed poor erections in 42% of these men [20].
To evaluate these ﬁndings, data should be incorporated with
regard to similar complaints prior to the onset of disease or
those of a control group.
The ﬁnding of reduced sexual arousal corresponding
with DSM-IV in women suﬀering from MS has not been
systematically covered in older literature. Beier’s afore-
mentioned retrospective inquiry identiﬁed a prevalence of
18%. Dyspareunia was speciﬁed in this study for 51% of
male and 22% of female patients. Neurologic surveys with
considerably smaller groups reported anorgasmy or reduced
ability to experience an orgasm in 64% of men and 58% or
12% of women [4, 21]. Libido disorders or decreased sexual
appetence (Diagnostic and Statistical Manual of Mental
Disorders Nomenclature) seem to be more common in
aﬀected men and is reported by approximately one-third of
this population.
The correlation between disturbances of pathways, the
overall degree of impairment and bladder dysfunctions with
sexual dysfunction was investigated by several researchers.
Sexual dysfunctions are exacerbated in the course of the
disease thus exhibiting the typical picture of other func-
tional impairments in MS patients. Moreover, in men it
is common to see impotency is largely associated with
bladder dysfunction and lesions of the pyramidal tract [22]
Women apparently do not present with sexual dysfunction
linked with bladder dysfunction to the same extent [23].
Diminished lubrication and disturbed sensation in the
genital region on the other hand, is frequently associated
with sexual dysfunctions in female MS patients [19, 24]. A
more recent study on women suﬀering from MS disclosed
that there is no correlation between sexual dysfunction and
a pathologic sympathetic skin response on sensory testing in
the genital region [25].
The communication of the diagnosis of MS has a far-
reaching eﬀect. This is corroborated by the fact that sexual
contentment, of both patients and their partners, ebbed
substantially after the diagnosis had been conveyed to them.
This does not appear to be related to the true degree of
organically explainable dysfunctions [20].
Sexual dysfunctions are considerably more frequently
multifactorial in nature than bladder dysfunctions, and may
be substantially determined by nonorganic causes. History-
taking is encumbered by the great variety ofsymptoms, aside
fromphysicians’andpatients’insecurityorreluctancetodeal
with the issue. Comparable data are thus hardly available.
The diagnostic procedure for sexual dysfunctions in
MS patients varies from the comparable situation of pre-
viously healthy subjects inasmuch that extended neurologic
diagnosis by exclusion can usually be neglected. Additional
urologic and gynecologic evaluation, is called for to rule
out nonneurological causes. Disturbed sensibility can to
some degree be objectively recorded by pudendal SSEP,
and sympathetic involvement by penile sympathetic skin
response (SSR).
Erectile dysfunction can most easily be subjected to
treatment. Earlier trials with pharmaceutical agents have
faded into the background after the introduction of phos-
phodiesterase inhibitors. Up to 90% of the patients related a
positive eﬀect [26].
Intracavernous prostaglandin injections and vacuum
pumps are reserved to exceptional cases. There is no
ascertained drug treatment of sexual dysfunctions in female
MS patients. The topical application of estrogens may, in
some cases, ameliorate lubrication.
4.2. Gastrointestinal Disorders. Constipation, and less fre-
quently, incontinence of feces are common symptoms
reported to thegeneralpractitioner, evenmore so by patients
in advancing years. Disordered bowel function is a typical
sequela of pontine and spinal lesions of the nervous system.
In these cases, concomitant sensorimotor disturbances are
usually present in addition to damaged autonomic ﬁbers.
So this permits data on the prevalence of gastrointestinal
disordersinMSpatients.However,speculationsprevailwhen
it comes to establishing connections between symptoms and
the underlying disease, or to identifying a speciﬁc site of
lesion. On direct questioning, 36 to 54% of the MS patients
complained of constipation [4]. The degree of constipation
is often more severe than the subjective aﬄiction. Symptoms
are furthermore felt to be milder than those of bladder
dysfunction which is usually present as well. It is quite
remarkable that nearly as many patients also relate—at
least temporary—fecal incontinence [27]. Constipation or
anal incontinence is particularly common as an additional
associated aspect of bladder dysfunction [28].
All MS patients complaining of constipation or non-
transitory incontinence of feces in terms of deﬁned criteria
should be sent to a gastroenterologic and proctologic
specialist for further evaluation. MS-induced constipation is
likely in the presence of notable pyramidal tract lesion with
spasticity due to general immobility, increased muscle tone
of the pelvic ﬂoor and semiparalyzed abdominal muscles.
A mechanism was described with paradoxical contractions4 Autoimmune Diseases
of the pelvic ﬂoor comparable to corresponding bladder
dysfunction [29]. No reliable data exist concerning the
question as to whether disturbed aﬀerences and lesions
of other autonomic or somatosensory nerves may also be
involved in causing MS-speciﬁc impairment of intestinal
m o t i l i t y .L e s i o n so ft h eb r a i ns t e m ,t h ev a g a ln u c l e u si n
particular, resultin slowed-downmotility ofthe entire upper
gastrointestinal tract down to the left colonic ﬂexure.
The diagnosis of functional intestinal trouble encom-
passes the aforementioned interdisciplinary clinical exami-
nations as well as the determination of colonic transit time,
anal manometry, defecography, and electromyography as
needed. The aforenamed examinations can help MS patients
to objectivate the symptoms they had reported in the ﬁrst
place [30]. Electromyographic examination of external anal
sphincter can either furnish proof of increased muscle tone
andincreased reﬂexactivation orruleoutpossibleperipheral
neurogenic lesions [31].
The therapeuticprocedureto improvedisorderedintesti-
nal motility is based on general and less on MS-speciﬁc
approaches: enhanced physical activity in spite of dis-
ability, adequate ﬂuid intake which makes the optimum
management of usually concomitant bladder dysfunction
a prerequisite, and dietary changes. In severe slow transit
constipation, macrogol is a helpful tool; outlet constipation
will respond to the administration of enemas. In patients
seriously aﬄicted, the anorectum may have to be cleared
digitally. Pronounced spasticity of the anal sphincter can
be mitigated by injections of Botulinum toxin. Trials with
loperamide or anticholinergic agents may be successful in
individual cases. What is mostly needed is care by perineal
pads, diapers, and other aids.
Within this context, brief mention should be made of a
special form of constipation: Overﬂow incontinence. When
the rectum of a severely constipated patient is crammed
w i t hf e c a lm a t t e rt h a th ei su n a b l et oe v a c u a t e ,h ei sg o i n g
to produce a scybalum with consecutive impaction of the
feces. Bacterial liquefaction of stools consecutively results in
incontinence with passage of liquid stools. This condition
requirestreatmentofconstipation.Managementfordiarrhea
would be utterly contraproductive. Digital rectal palpation
usually points to the right direction when the patient’s
rectum is ﬁlled up with stools.
4.3. Cardiovascular Disorders. Symptoms indicative of char-
acteristic cardiovascular disorder in MS rarely seem related.
When questioned, however, many patients complain of poor
physicalﬁtness andearly exhaustion, buttheyfail tomention
symptoms of orthostatic dysregulation, neurocardiogenic
syncopes, or cardiac dysrhythmias. Through autonomic
functional diagnostic workup in adequately equipped lab-
oratories, a few work groups nonetheless succeeded in
proving rather frequent disorders of the cardiovascular
system.Olderstudies[32]aswell asmorerecentpublications
[33] concurred in observing no abnormalities on orthostatic
tests. Some other work groups though found orthostatic
dysregulations in up to 25% of the MS patients [34, 35].
Similar results hold true for clinical symptoms. One should
note that orthostatic dysregulation—the cardinal symptom
of many autonomic disorders—never comes as the ﬁrst
manifestation or episode equivalent of multiple sclerosis.
Even in the late stage, it is at most seen in a small group of
patients.
Several work groups conducted a standardized series
of parasympathetic and sympathetic tests in selected or
consecutive groups of patients, and partly controls. Unfor-
tunately, this study was originally designed to look at
peripheral autonomic disorders (diabetic polyneuropathy),
and thus not validated for central autonomic disorders.
The results and correlations disclosed do not make for a
uniform picture: Merkelbach and coworkers found hand
grip test (43% of the patients examined) to be the most
conspicuous test suggesting sympathetic dysfunction. A
diﬀerencebetweenthevaried coursesofdisease wasnotseen.
McDougall reported the 30:15 ratio—and thus a mostly
parasympathetic test in 16% of his patients—being the most
frequent pathology. De Seze cites blood pressure monitoring
in orthostasis—a test of sympathetic function—in 18%
as the most common remarkable feature that correlates
signiﬁcantly with a primary or secondary chronic course
of disease. It was merely in Valsalva’s maneuver—a largely
parasympathetic test—that Flachenecker [36] found a major
diﬀerence between the results for active and inactive disease.
There are no speciﬁc approaches to treat the rare ortho-
static problems in MS. Basic management consists in ade-
quateﬂuid intakeand a dietrich in sodium. Patients will also
beneﬁt from wearing elastic stockings. Medication is useful
to increase blood volume and the peripheral vessels tone, for
instance by using ﬂudrocortisone or a sympathomimetic.
4.4. Other Dysfunctions of the Autonomic System. The main
sympathetic skin response was studied in various groups
of MS patients. Several work groups [33, 35, 37]r e p o r t e d
pathologic results in 40 to 50% of the patients. They
described both, missing and delayed response, with leg leads
being the chief provider of pathologic results. Abnormal
measurements (in up to 94%) were scarcely recorded [38].
Clinical symptoms regarding autonomic disturbances were
not always related synchronously. A positive correlation with
the duration of illness was seen in some patient groups, in
others this pertained to the MS-induced disabilities.
Only a few studies used pupillometric tests in MS
patients. The charming idea of observing a control system
with sympathetic and parasympathetic impacts on pupil size
is limited by the fact that many patients have a history
of optic neuritis, which is likely to disrupt physiologic
regulation later on. These measurements have failed to
establish a uniform cardinal parameter. The conclusions
drawn from them are incongruous [39].
Olderpublicationsclaimedthathypo- orevenanhidrosis
of the lower limbs was the most common disturbance in
thermoregulatory sweating in MS patients [40]. Patients
in advanced stages of the disease are generally stricken by
considerable spinal aﬄiction.
Some authors [41] describe positive correlation between
sympathetic vasomotor dysfunction and fatigue in MSAutoimmune Diseases 5
patients. These observations have not been conﬁrmed by
larger studies and their contribution to the understanding of
fatigue in MS remains uncertain.
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